Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB.

Clin Cancer Res. 2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15.

2.

[Emergency Medicine in Remote Settings].

Leischker A, Holst FG.

Dtsch Med Wochenschr. 2018 Aug;143(16):1193-1200. doi: 10.1055/s-0043-111844. Epub 2018 Aug 7. Review. German.

PMID:
30086566
3.

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA.

Sci Rep. 2017 Aug 31;7(1):10240. doi: 10.1038/s41598-017-10717-z.

4.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2017 Jun 30;7:46873. doi: 10.1038/srep46873.

5.

Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.

Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C.

Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17. doi: 10.1016/j.ajog.2017.05.068. Epub 2017 Jun 24.

PMID:
28599900
6.

Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.

Soeberdt M, Molenveld P, Storcken RP, Bouzanne des Mazery R, Sterk GJ, Autar R, Bolster MG, Wagner C, Aerts SN, van Holst FR, Wegert A, Tangherlini G, Frehland B, Schepmann D, Metze D, Lotts T, Knie U, Lin KY, Huang TY, Lai CC, Ständer S, Wünsch B, Abels C.

J Med Chem. 2017 Mar 23;60(6):2526-2551. doi: 10.1021/acs.jmedchem.6b01868. Epub 2017 Mar 13.

PMID:
28218838
7.

ESR1-Amplification-Associated Estrogen Receptor α Activity in Breast Cancer.

Holst F, Singer CF.

Trends Endocrinol Metab. 2016 Nov;27(11):751-752. doi: 10.1016/j.tem.2016.08.002. Epub 2016 Aug 30. No abstract available.

PMID:
27595547
8.

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.

Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB.

Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.

9.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 Jun 24;6:27960. doi: 10.1038/srep27960. No abstract available.

10.

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 May 10;6:25521. doi: 10.1038/srep25521. Erratum in: Sci Rep. 2016 Jun 24;6:27960. Sci Rep. 2017 Jun 30;7:46873.

11.

Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.

Holst F.

World J Clin Oncol. 2016 Apr 10;7(2):160-73. doi: 10.5306/wjco.v7.i2.160. Review.

12.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB.

Oncotarget. 2015 Jan 20;6(2):1327-39.

13.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1.

PMID:
24995579
14.

ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous.

Moelans CB, Holst F, Hellwinkel O, Simon R, van Diest PJ.

PLoS One. 2013 Dec 18;8(12):e84189. doi: 10.1371/journal.pone.0084189. eCollection 2013.

15.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

16.

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB.

PLoS One. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873. Epub 2013 Feb 5.

17.

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A.

Breast Cancer Res Treat. 2013 Feb;137(3):745-53. doi: 10.1007/s10549-013-2406-4. Epub 2013 Jan 16.

PMID:
23322234
18.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

19.

Role of cyclin D1 amplification and expression in vulvar carcinomas.

Choschzick M, Hess S, Tennstedt P, Holst F, Bohlken H, Gieseking F, Mahner S, Woelber L, Simon R, Sauter G.

Hum Pathol. 2012 Sep;43(9):1386-93. doi: 10.1016/j.humpath.2011.11.014. Epub 2012 Mar 9.

PMID:
22406359
20.

On the evidence for ESR1 amplification in breast cancer.

Holst F, Moelans CB, Filipits M, Singer CF, Simon R, van Diest PJ.

Nat Rev Cancer. 2012 Jan 24;12(2):149. doi: 10.1038/nrc3093-c3. No abstract available.

PMID:
22270954
21.

PPFIA1 and CCND1 are frequently coamplified in breast cancer.

Dancau AM, Wuth L, Waschow M, Holst F, Krohn A, Choschzick M, Terracciano L, Politis S, Kurtz S, Lebeau A, Friedrichs K, Wencke K, Monni O, Simon R.

Genes Chromosomes Cancer. 2010 Jan;49(1):1-8. doi: 10.1002/gcc.20713.

PMID:
19787783
22.

Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions.

Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G, Simon R.

J Pathol. 2008 Oct;216(2):151-7. doi: 10.1002/path.2405.

PMID:
18720455
23.

Estrogen receptor gene amplification occurs rarely in ovarian cancer.

Issa RM, Lebeau A, Grob T, Holst F, Moch H, Terracciano L, Choschzick M, Sauter G, Simon R.

Mod Pathol. 2009 Feb;22(2):191-6. doi: 10.1038/modpathol.2008.130. Epub 2008 Aug 8.

24.

[Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca].

Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M.

Internist (Berl). 2007 Jul;48(7):727-30. German.

PMID:
17541532
25.

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R.

Nat Genet. 2007 May;39(5):655-60. Epub 2007 Apr 8.

PMID:
17417639
26.

Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria.

Hemmer CJ, Holst FG, Kern P, Chiwakata CB, Dietrich M, Reisinger EC.

Trop Med Int Health. 2006 Jun;11(6):817-23.

27.

Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease.

Finckh U, von der Kammer H, Velden J, Michel T, Andresen B, Deng A, Zhang J, Müller-Thomsen T, Zuchowski K, Menzer G, Mann U, Papassotiropoulos A, Heun R, Zurdel J, Holst F, Benussi L, Stoppe G, Reiss J, Miserez AR, Staehelin HB, Rebeck GW, Hyman BT, Binetti G, Hock C, Growdon JH, Nitsch RM.

Arch Neurol. 2000 Nov;57(11):1579-83.

PMID:
11074789
28.

Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity.

Holst FG, Hemmer CJ, Foth C, Seitz R, Egbring R, Dietrich M.

Am J Trop Med Hyg. 1999 Jan;60(1):99-104.

PMID:
9988331
29.

Inappropriate secretion of antidiuretic hormone and hyponatremia in severe falciparum malaria.

Holst FG, Hemmer CJ, Kern P, Dietrich M.

Am J Trop Med Hyg. 1994 May;50(5):602-7.

PMID:
8203710
30.

Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study.

Hemmer CJ, Kern P, Holst FG, Nawroth PP, Dietrich M.

Am J Trop Med Hyg. 1991 Nov;45(5):608-12.

PMID:
1951871
31.

[Brucellosis-induced granulomatous non-puerperal mastitis--a case report].

Gilbert P, Holst F, Rossbach J, Pauli HK.

Geburtshilfe Frauenheilkd. 1991 Sep;51(9):747-9. German.

PMID:
1743476
32.

Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels.

Hemmer CJ, Kern P, Holst FG, Radtke KP, Egbring R, Bierhaus A, Nawroth PP, Dietrich M.

Am J Med. 1991 Jul;91(1):37-44.

PMID:
1858827
33.

Degradation of human plasma fibrin stabilizing factor XIII subunits by human granulocytic proteinases.

Klingemann HG, Egbring R, Holst F, Gramse M, Havemann K.

Thromb Res. 1982 Dec 15;28(6):793-801.

PMID:
6188235
34.

Digestion of alpha 2-plasmin inhibitor by neutral proteases from human leucocytes.

Klingemann HG, Egbring R, Holst F, Gramse M, Havemann K.

Thromb Res. 1981 Dec 1-15;24(5-6):479-83. No abstract available.

PMID:
6178175
35.

DIGITAL COMPUTERS--WHAT THEY ARE.

HOLST FB.

Arch Environ Health. 1963 Sep;7:296-302. No abstract available.

PMID:
14052762
36.

On the State of Medicine in Norway.

Holst F.

Br Foreign Med Rev. 1837 Oct;4(8):541-551. No abstract available.

Supplemental Content

Support Center